Endologix — Q3 2010 Earnings Presentation
88 slides from Endologix's earnings presentation, Oct 27, 2010
Slide 1: Third Quarter 2010 Results and Nellix Acquisition
ENDOLOGIX Innovation Taking Shape Third Quarter 2010 Results and Nellix Acquisition October 27, 2010 ENDOLOGIX
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, statements relating to the potential benefits of Endologix, Inc.’s proposed acquisition of Nellix, Inc., including expected ope
Slide 3: 3Q 2010 Results
3Q 2010 Results Revenue of $17.9 million, up 30% y/y Domestic revenue $15.3 million International revenue $2.6 million Gross margin of 79% Net loss of $466,000 or $0.01 per share Includes $1.4 million of legal and business development Cash flow positive Cash and cash equivalents of $22.9 million Gui
Slide 4: Driving for Market Leadership
Driving for Market Leadership Innovation leader in AAA with strong momentum towards aortic market leadership Continuing to invest for growth in a highly competitive market Larger, strengthened sales force R&D programs focused on expanding addressable market Demonstrated ability to execute and gain m
Slide 5: Nellix Acquisition Highlights
Nellix Acquisition Highlights Provides ELGX with next generation EVAR technology platform Potential to reduce secondary interventions, long-term surveillance, radiation exposure and healthcare costs Simple and intuitive procedure steps Treats more anatomies than other AAA devices Expands AAA market
Slide 6: Current EVAR Limitations
Current EVAR Limitations Secondary interventions are required in 18 – 20% of EVAR patients Requires lifetime surveillance Higher mortality ~60% of secondary interventions are caused by endoleaks1 Nellix device is the only EVAR technology that seals the AAA sac and has the potential to eliminate endo
Slide 7: Technology Overview
Technology Overview Highly Differentiated Aneurysm Filling/Sealing Platform Endobags are filled with a biostable polymer Integrated Endoframes pave blood flow lumens to the legs Next Gen Anatomic Fixation Conforms, seals and stabilizes all AAA anatomies No need for barbs, hooks or continuous radial
Slide 8: Nellix Implant Procedure
Nellix Implant Procedure Unexpanded Endoframes Expanding Endoframes Polymer Filled Endobag Completion Angiogram ENDOLOGIX
Slide 9: 100% Aneurysm Exclusion
100% Aneurysm Exclusion ENDOLOGIX
Slide 10: Exceptional Clinical Results
Exceptional Clinical Results 34 Patients (follow –up to 2 years) Over 50% of implants are outside the indications for other EVAR devices Minimal endoleaks and secondary interventions with 1st generation device 100% freedom from AAA-related mortality No aneurysm ruptures No stent graft migration Stro
Slide 11: Nellix Physician Feedback
Nellix Physician Feedback Product / Technology Has the capability to treat a wide range of anatomies Short / no neck AAAs Large diameter necks Aneurismal iliac Hypogastric preservation Procedure Simple, intuitive steps Predictable procedure times and outcomes for both simple and complex anatomies Li
Slide 12: AAA Competitive Landscape
AAA Competitive Landscape Company Device Profile Neck Length Neck Diameter ELGX AFX 19F 15mm 32mm MDT Endurant 18F—20F 10mm 32mm Cook Zenith LP 16F—18F 15mm 32mm Gore Repositionable 18F—20F 15mm 29mm Trivascular Ovation 14F—15F 7mm 32mm Nellix Nellix* 18F—19F 5mm 34mm JNJ Incraft 1 4F 15mm 32mm Teru
Slide 13: EU 2010 EVAR Market
EU 2010 EVAR Market ¡ \Large growing market with good historical adoption of new vascular technology (perc valves, etc) ¡ Nellix + ELGX new product portfolio depth provides ideal timing to establish direct channel $4.6M $140M EU EVAR Market ELGX Sales ENDOLOGIX
Slide 14: ELGX Planned New Product Pipeline
ELGX Planned New Product Pipeline IntuiTrak New Sizes Europe AFX U.S. Nellix Europe PEVAR U.S. Ventana Europe Xpand Europe AFX2 U.S. Aortic Stent Europe Ventana U.S. Nellix U.S. 2011 2012 2013 2014 2015 IntuiTrak New Sizes International IntuiTrak Japan Nellix International Ventana International Xpan
Slide 15: ELGX Market Opportunities
ELGX Market Opportunities Infrarenal Juxtarenal Thoracic 2015 $400M $300M $1B Aortic Stent Ventana $1.7B AFX TAA Stent Graft Xpand PEVAR Nellix ENDOLOGIX
Slide 16: Acquisition Agreement
Acquisition Agreement All stock transaction At closing Essex Woodlands will invest $15M – 2 ELGX board seats Estimated 11% dilution at initial deal closing Deal Structure Upfront Stock at Closing $15M 30% Milestones $10M OUS sales (TTM) $20M* 40% PMA Approval $15M 30% Total $50M 100% * Ranges from $
Slide 17: Essex Med Tech Portfolio
Essex Med Tech Portfolio Early Stage PIPE Late Stage ENDOLOGIX
Slide 18: Transaction Milestones
Transaction Milestones Anticipated Timing: 2011 2012 2013 2014 2015 Technology transfer to ELGX Build EU direct sales organization Nellix International launch U.S. IDE clinical trial PMA approval US launch EU Launch Enrollment ENDOLOGIX
Slide 19: Anticipated ROI
Anticipated ROI Incremental revenue starting in 2011 with estimated 2016 Nellix revenue of ~$100M –At 3.5X sales = $350M potential increase in 2016 market cap Direct EU sales force to capture market share and leverage full ELGX product line over time Improved OUS margins Back-end loaded structure mi
Slide 20: Financial Guidance
Financial Guidance 2011 revenues of $78M - $82M 2011 loss of $0.25 - $0.30 per share Nellix R&D: ~$13.0M or ($0.23) EU Sales Force: ~$5.7M or ($0.10) Deal Amortization & Integration: ~$2.2M or ($0.04) Expect core business profitability in 2011 Expect total company profitability by Q4 2012 Operating
Slide 21: Post Acquisition Balance Sheet
Post Acquisition Balance Sheet ASSETS Cash $40M Total Current Assets $60M Net Fixed Assets $3M Goodwill & Intangibles $47M TOTAL ASSETS $110M LIABILITIES & EQUITY Total Current Liabilities $12M Long Term Liabilities $1M Total Liabilities $13M Total Equity $97M TOTAL LIABILITIES & EQUITY $110M Strong
Slide 22: Nellix Acquisition Summary
Nellix Acquisition Summary Strategic Drivers Compelling Factors Most promising & disruptive new EVAR technology Addresses the limitations of current devices Market expanding Excellent growth opportunity for ELGX Nellix strengthens & complements ELGX pipeline Simple, intuitive procedure Physician pul
Slide 23: Endoluminal Aortic Aneurysm Repair Using Sac Anchoring Endoprosthesis
Endoluminal Aortic Aneurysm Repair Using Sac Anchoring Endoprosthesis Single Center Experience in Latvia Dainis Krievins, MD and J. Savlovskis, K. Kisis, M. Gedins, C. Donayre, C. Zarins Pauls Stradins University Hospital Riga, Latvia International Congress Phoenix, Arizona March 2010
Slide 24: Unresolved problems with EVAR
Unresolved problems with EVAR Many patients have unsuitable aortic neck and iliac anatomy and thus are not candidates for EVAR Persistent and new onset endoleaks Aneurysm enlargement, secondary procedures Long-term positional instability Migration, secondary procedures, risk of rupture
Slide 25: The Nellix Endoprosthesis
The Nellix Endoprosthesis A new sac-anchoring device Not dependent on proximal and distal fixation mechanisms Obliterates aneurysm sac, eliminating endoleaks
Slide 26: Sac Anchoring Endoprostheses
Sac Anchoring Endoprostheses Endobag Stainless Steel Endoframes Polymer Filled Endobags
Slide 27: Device implantation
Device implantation Unexpanded endoframes Expanded endoframes (flow channel) Polymer filled endobag Completion angiogram
Slide 28: Purpose
Purpose To review our initial experience using the Nellix sac anchoring endoprosthesis in patients with favorable unfavorable anatomy All patients signed informed consent and were enrolled in an IRB-approved prospective clinical trial Follow-up included CT scans at 30, 180 and 360 days
Slide 29: Case example
Case example favorable anatomy, small aneurysm pre post 1 month CT scan
Slide 30: Case example
Case example favorable anatomy, large aneurysm 1 mo 6 mo 1 year
Slide 31: Case example
Case example unfavorable anatomy, short, angulated neck month CT scan
Slide 32: Case example
Case example bilateral common iliac artery aneurysm Pre Post
Slide 33: Case example
Case example unfavorable anatomy, funnel neck, iliac aneurysm 3.5 cm CIA. Nellix iliac extender Internal iliac flow preserved
Slide 34: Case example
Case example short angulated neck & dilated common iliac arteries Iliac aneurysm Nellix iliac extender Internal iliac patent
Slide 35: Patient population
Patient population 16 patients treated from 2008-2009 Age 68±9 years (range 53-83 years) Comorbidities: - CAD 7 (44%) - Hypertension 9 (56%) - DM 2 (13%) - Smoking 3 (19%) - COPD 3 (19%)
Slide 36: Aneurysm Morphology
Aneurysm Morphology Aortic aneurysm AAA diameter: 6.0±0.7 cm (4.3-7.2 cm) Lumen diameter 43±7 mm (33-55 mm) Neck morphology Diameter 23±3 mm (17-31 mm) Length 19±12 mm (5-35 mm) Angle 37±18 degrees (9—72 degrees)
Slide 37: Unfavorable anatomy patients
Unfavorable anatomy 9 patients (56%) Adverse morphology – does not meet IFU criteria of current FDA approved endografts Neck length <9 mm 7 patients (44%) Neck angulation >60 degrees 3 patients (19%) CIA extending to hypogastric artery 3 patients (19%)
Slide 38: Procedural Results
Procedural Results 16 patients Procedural success 16/16 100% Procedure time 56±22 (33-120 min) Volume of polymer fill 72±31 (35-130ml) Iliac extenders 4 (3 patients)
Slide 39: 30 Day Results
30 day Results 30 day mortality 0% 30 day morbidity 0% Secondary procedures 0% Significant adverse events 0%
Slide 40: Follow up evaluation
Follow up evaluation Follow up time 8±4 months (3-15 mo) One major adverse clinical event —Death from MI at 10 months — 6 months CT OK Overall mortality 1/16 6.3% AAA related mortality 0% No secondary treatments No AAA or device related adverse events
Slide 41: Follow up imaging
Follow up imaging Follow up CT scans - 30 day 16/16 100% - 6 months 9/16 (100% of expected) - 12 month 2/15 (100% of expected) One patient had a small amount of contrast visible between the endobag and AAA sac at 30 days which was not present at 60 days and 6 months
Slide 42: Follow-up CT imaging
Follow-up CT imaging 9 patients at 6 month AAA diameter – no change 5.93 ± 0.22 (baseline) 5.98 ± 0.23 (1month) p=0.22 5.94 ± 0.22 (6 months) AAA volume – no change 243 ± 29 cm2 (1 month) p=0.24 238 ± 27 cm2 (6 months) No movement of lumen endoframes No endoleaks
Slide 43: Summary
Summary 56% of patients had anatomy unsuitable for FDA approved endografts 100% procedural success Complete aneurysm exclusion, no endoleaks Exclusion of common iliac aneurysms with preservation of internal iliac flow Favorable early results
Slide 44: Discussion
Discussion Sac anchoring endoprostheses have the potential to overcome current EVAR limitations Adverse neck anatomy / “No neck” Elimination of persistent or new onset endoleaks Simple treatment of iliac aneurysms without hypogastric occlusion Improved long-term device stability Preliminary results
Slide 45: Thank You
Thank You Pauls Stradins University Hospital Riga, Latvia
Slide 46: In the Future, You're Both Wrong: Devices That Fill the Aneurysm Will Take Over
In the Future, You’re Both Wrong Devices That Fill the Aneurysm Will Take Over VIVA CONTROVERSIES FORUM: Treatment for Short Neck AAA Anatomy In the Future, You’re Both Wrong: Devices That Fill the Aneurysm Will Take Over Andrew Holden, MD Auckland City Hospital Auckland, New Zealand VIVA 10
Slide 47: Faculty Disclosure
In the Future, You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Faculty Disclosure Andrew Holden, MD For the 12 months preceding this CME activity, I disclose the following types of financial relationships: Consulted for: Research, clinical trial, or drug Abbott Vascular Laboratories
Slide 48: Short Neck AAA: The Challenge
In the Future, You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Short Neck AAA: The Challenge Current EVAR devices can only treat ~60% of infra-renal AAA anatomies because they require a length of proximal neck for seal +/- fixation Andrew Holden. MD VIVA 10
Slide 49: Short Neck AAA: The Challenge
In the Future, You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Short Neck AAA: The Challenge Fenestrated and branch grafts can treat short necked AAAs, avoiding the early morbidity of open repair. Challenges include: Device availability Operator experience Procedural complexity Branc
Slide 50: Short Neck AAA: The Challenge
In the Future, You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Short Neck AAA: The Challenge A device that fills the aneurysm sac rather than relies on graft-wall apposition for sealing has the potential to treat almost all infra-renal AAA anatomies. Andrew Holden, MD VIVA 10
Slide 51: Nellix Endovascular System
In the Future, You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Nellix Endovascular System A radically different endovascular system for AAA repair Major components: Endoframes: maintain a flow lumen to each leg Endobags: filled with a polymer that quickly sets to fill the aneurysm sa
Slide 52: Nellix Endovascular System
In the Future, You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Nellix Endovascular System Devices introduced Endoframes deployed Andrew Holden, MD VIVA 10
Slide 53: Nellix Endovascular System
In the Future, You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Nellix Endovascular System Endobags pre-filled Endobag polymer fill Andrew Holden, MD VIVA 10
Slide 54: Nellix Endovascular System
In the Future, You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Nellix Endovascular System 5mm long neck Andrew Holden, MD VIVA 10
Slide 55: Nellix Endovascular System
In the Future, You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Nellix Endovascular System Unful endobags Position and deploy endoframes Pre-fill endobags and check DSA Andrew Holden, MD VIVA 10
Slide 56: Nellix Endovascular System
In the Future, You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Nellix Endovascular System Fill endobags with polymer and cure Check angiogram Post-dilate endoframes Andrew Holden, MD VIVA 10
Slide 57: Nellix Endovascular System
In the Future You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Nellix Endovascular System Completion angiogram 30-day CT 30-day CT Andrew Holden, MD VIVA 10
Slide 58: Post-Procedural Imaging
In the Future You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Post-Procedural Imaging Pre-contrast Post-contrast Thrombus, endobags (arrows) and endoframes easily seen Andrew Holden, MD VIVA 10
Slide 59: Nellix Endovascular System advantages
In the Future You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Nellix Endovascular System Major advantages of the system: Because the endobags are sealing the aneurysm, most anatomies (including short necks) can be treated Because the blood volume in the aneurysm sac is filled by the
Slide 60: Short Neck AAA
In the Future You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Short Neck AAA Short proximal neck with” posterior bulge” Andrew Holden, MD VIVA 10
Slide 61: Short Neck AAA
In the Future You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Short Neck AAA Short proximal neck with “posterior bulge” Unsubtracted Subtracted Andrew Holden, MD VIVA 10
Slide 62: Short Neck AAA
In the Future You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Short Neck AAA Short proximal neck with “posterior bulge” Lateral Projection X ray @ 30 days Andrew Holden, MD VIVA 10
Slide 63: Short Neck AAA
In the Future You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Short Neck AAA Short proximal neck with “posterior bulge” Pre-procedural CT Post-procedural CT Andrew Holden, MD VIVA 10
Slide 64: First 34 Patients
In the Future You’re Both Wrong Devices That Fill the Aneurysm Will Take Over First 34 Patients Riga, Latvia (D Krievins) 16 patients Auckland, NZ (A Holden, A Hill) 12 patients Aortic neck length: 22.1 mm (5.0 – 50 mm) Technical success: 100% Rupture: 0% Conversion to open repair: 0% Secondary inte
Slide 65: Conclusions
In the Future You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Conclusions The Nellix endovascular systems is a radically different approach to EVAR Experience is limited but early results suggests short neck AAA can be successfully treated with this system Type 2 and other endoleaks
Slide 66: Celebrating 8 Years of Education in Vascular Medicine
In the Future You’re Both Wrong Devices That Fill the Aneurysm Will Take Over Celebrating 8 Years of Unsurpassed Education in Vascular Medicine and Intervention VIVA 10
Slide 67: Endoluminal Aortic Aneurysm Repair Using a Novel Sac Anchoring Endoprosthesis
Endoluminal Aortic Aneurysm Repair Using a Novel Sac Anchoring Endoprosthesis: Favorable vs. Adverse Anatomy Frans Moll, Dainis Krievins, Andrew Holden, Janis Savlovskis, Carlos Calderas, Carlos Donayre, Barry Katzen and Christopher Zarins The University of Utrecht, Utrecht, The Netherlands and the
Slide 68: Disclosure
Disclosure This study was supported by Nellix, Inc., Palo Alto, CA, USA The device is produced by Nellix, Inc. One or more investigators have a financial interest in Nellix
Slide 69: Unresolved problems with EVAR
Unresolved problems with EVAR Endoleaks Aneurysm enlargement and rupture Migration Long term positional stability Unsuitable anatomy Aortic neck Iliac arteries
Slide 70: Novel Sac Anchoring Endoprosthesis
Novel Sac Anchoring Endoprosthesis Dual balloon expandable endoframes provide flow lumens Polymer filled endobags obliterate aneurysm sac, provide support and eliminate endoleak space Fixation is not dependent on proximal neck and iliac arteries Common iliac aneuryms are treated with preservation of
Slide 71: Purpose
Purpose Review results of prospective, multi-center, clinical trial 4 clinical sites: Latvia, New Zealand, Venezuela, Colombia 34 patients treated from 2008-2010 Follow up 15 ± 6 months Compare patients with favorable vs. adverse anatomy Favorable anatomy = suitable for current endografts Adverse an
Slide 72: Sac anchoring endoprosthesis
Sac anchoring endoprosthesis Favorable anatomy Pre Post 1 month CT scan
Slide 73: Adverse anatomy
Adverse anatomy neck length 11 mm, funnel neck, common iliac aneurysm 3.5 cm CIA. Nellix iliac extender Internal iliac flow preserved
Slide 74: Adverse anatomy
Adverse anatomy neck length 5 mm; neck angle 72 degrees; 28 mm common iliac aneurysm lliac aneurysm Nellix extender Internal iliac patent
Slide 75: Patient population
Patient population Age: 71±8 years (range 53-84 years) Gender: men 91%, women 9% Comorbidities CAD 56% CHF 20% Hypertension 68% DM 12% Smoking 50% PVD 21% Aortic aneurysm: 5.8 ± 0.8 cm (4.2-7.6 cm) Neck diameter 24 ± 3 mm(18-31 mm) Neck length 21 ± 12 mm(5-50 mm) Neck angle 37± 15 degrees (9-72 degr
Slide 76: Adverse anatomy
Adverse anatomy unsuitable for FDA approved devices Patients with adverse anatomy 17 50% 6 pts had two or more adverse measures Patients with favorable anatomy 17 50% Adverse anatomy measures Neck length < 10 mm 8 24% Neck angulation > 60 degrees 3 9% Iliac aneurysm diameter > 23 mm 13 38%
Slide 77: Procedural Results
Procedural Results 34 patients Procedural success 34/34 100% Procedure time 70 ± 32 min Volume of polymer fill 73 ± 33 ml Blood loss 165 ± 107 ml 30 day mortality 1/34 2.9% Multisystem organ failure Non-device related (post-procedure CT and autopsy) Endoleak 2/34 5.9% Limited space endoleak on CT sc
Slide 78: Limited space endoleaks
Limited space endoleaks Contrast in space between endobag and aneurysm wall on post-op CT scan — 2 patients Spontaneously resolved in 60 days Endobag does not cover bottom of aneurysm Endoleak persists; no change in aneurysm size Resolved with iliac extender at 15 months 30 days 1 year
Slide 79: Follow up evaluation
Follow up evaluation Follow up time 15 ± 6 months (7-27 mo) All-cause mortality 2/34 5.9% 1 peri-operative death 1 late death at 10 months due to CHF Normal CT scan at 6 months No surgical conversions No ruptures One secondary treatment Endovascular treatment of persistent endoleak at 15 months No n
Slide 80: No change in aneurysm size
No change in aneurysm size Aneurysm diameter (based on the maximum and minimum diameter at the level of maximum sac crossectional area) (mm) 60.0 40.0 20.0 0.0 Baseline CTA 1. month follow-up 6. month follow-up 1.year follow-up Mean ± 95% CI. Follow-up period Pre-op 1month 6month 12months 24months
Slide 81: No change in device position
No change in device position Vertebra-to-stent distance E and G (mm) 40.0 35.0 30.0 25.0 20.0 15.0 10.0 right e left g N=33 N=30 N=19 1.month follow-up 6. month follow-up 1. year follow-up Follow-up period Mean ± 95% CI. SMA to Top Endoframe Distance 1 mo: 16.6 ± 2.7 mm 6 mo: 18.4 ± 2.8 mm 12 mo: 17
Slide 82: Conclusions
Conclusions Patients with both favorable and adverse anatomy can be successfully treated using this novel sac anchoring endoprosthesis Complete fill of aneurysm sac eliminates the endoleak space Common iliac aneurysms can be treated with preservation of internal iliac flow
Slide 83: Discussion
Discussion Sac anchoring endoprostheses have the potential to overcome current EVAR limitations Adverse neck anatomy / “No neck” aneurysms Common iliac aneurysms with patent hypogastric arteries New and persisting endoleaks Migration of endograft Early results are promising Longer-term follow up is
Slide 84: Cover Story: Fillable Endovascular Aneurysm Repair
COVER STORY Fillable Endovascular Aneurysm Repair An early look at a next-generation EVAR technology that may address some current limitations and improve clinical outcomes. BY CARLOS DONAYRE, MD; GEORGE E. KOPCHOK, BS; AND RODNEY A. WHITE, MD Approximately 19% of patients develop an endoleak or end
Slide 85: Cover Story
COVER STORY Endovascular (Palo Alto, CA) has designed a fillable, sac-anchoring, low-profile endovascular device. The Nellix technology encompasses a fully contained, polymer-filled endobag, which conforms perioperatively to the specific shape of the patient’s aneurysm while providing anchoring and
Slide 86: Cover Story
COVER STORY long-term endoleaks caused by aneurysm remodeling and separation of modular components. Minimizing Migration and Lateral Movement Successful EVAR treatment by current stent graft devices is typically marked by AAA sac shrinkage. Aortic aneurysm shrinkage has been shown to increase the bi
Slide 87: The Frontier of New EVAR Device Technology
COVER STORY The Frontier of New EVAR Device Technology Andrew Holden, MBChB, FRANZCR, provides his unique perspective on EVAR and a look at his latest trial experiences with new technology. Endovascular Today: How is your perspective as a New Zealand practitioner particularly unique regarding the cu
Slide 88: Cover Story
COVER STORY commercially approved EVAR devices. This data was obtained from the Society for Vascular Surgery. Patients in the trial are screened to meet a predetermined set of inclusion and exclusion criteria. The primary goals of the study are to determine the technical success of the device, the a